Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Novo Nordisk A/S (ADR) (NVO): Still a Buy, Despite the Tresiba Setback

Shares of Novo Nordisk A/S (NYSE:NVO) are trying to recover from a recent sell-off that occurred after the FDA rejected its new drug Tresiba — citing lack of a pre-approval cardiovascular outcomes study. Tresiba is an insulin analog, which is injected subcutaneously three-times a week to help control the blood sugar level of those with diabetes. Shares plummeted almost 15% on this disappointing news. But the real question now is if this setback has changed the long-term potential of Novo Nordisk or are the shares still a buy?

Novo Nordisk A/S (ADR) (NYSE:NVO)This rejection does prove that how serious the FDA has become in recent years when it comes to the safety and risk-benefit analysis of potential new diabetes drugs. I’ve noticed several recent moves by the FDA that second my opinion — from Amylin Pharmaceuticals LLC (NASDAQ:AMLN)‘s Bydureon to Bristol Myers Squibb Co. (NYSE:BMY)AstraZeneca plc (ADR) (NYSE:AZN)‘s SGLT-2 inhibitor Dapagliflozin. The FDA twice declined to approve Bydureon in 2010, with its most serious concern being that the drug might contribute to heart rhythm abnormalities. Similarly, in 2011 the FDA decided not to approve the novel diabetes drug Dapagliflozin until drug-makers Bristol-Myers Squibb and AstraZeneca supply more data on the drug’s benefits and risks.

Though Tresiba proved its efficacy, Novo Nordisk was unable to convince the FDA about the safety of the drug. Despite the fact that both Europe and Japan have approved Tresiba, the FDA has now asked for a new study as a prerequisite for the approval. Moreover, Novo got a warning letter from the FDA, citing other facility issues as well. Novo’s management now faces a dilemma, as they aren’t sure what the next step should be. The major issue is with the design of the study and if that may or may not be completely acceptable to the FDA. Another issue is the length of the trial, as it might take years before the definite results of the study could be known.

I believe, this setback gives Novo’s direct competitor Sanofi SA (ADR) (NYSE:SNY), a major advantage. Sanofi has Lantus, which is a long-acting insulin that is taken once a day for diabetes treatment. Sanofi is also working on a new follow-on to Lantus, which is expected to launch in 2015. Moreover, concerns about what will happen with Tresiba in Europe and Japan remain.

Nevertheless, the setback for Tresiba is hardly a disaster as Novo has a strong future pipeline and its fundamentals remain strong. I believe, this setback will have a very little effect on the Novo Nordisk’s future earnings as it still has the Insulin detemir, a long-acting human insulin analogue for maintaining the basal level of insulin, which the company markets under the trade name Levemir.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.